Prakt. lékáren. 2010; 6(4): 192-197

New medicinal substances in extemporaneous prescription, part 2 - dexpanthenol

PharmDr.Jan Hašek
Lékárna U Matky Boží, Doksy

The present article deals with dexpanthenol as a pharmaceutical substance that is used in the treatment of skin and mucosal conditions and

can be used to prepare medicinal products in a pharmacy. Dexpanthenol is a universal as well as very safe drug being used in otorhinolaryngology

and, in particular, dermatology. The paper describes the properties, mechanism of action and use of dexpanthenol not only as a drug

promoting cellular metabolism, but also deals with the role of the substance as a component of the natural hydrating factor, or moisturizer,

in a wider context during adjuvant therapy for atopic dermatitis. Also, galenic properties and options of incorporating into medicinal products

are described. The last section includes examples of prescriptions intended for extemporaneous preparation in pharmacies. Emphasis

was placed on suitability of the prescriptions corresponding with the current knowledge of the treatment of skin conditions.

Keywords: dexpanthenol, epithelization, atopic dermatitis, moisturizing substance, extemporaneous prescription

Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hašek J. New medicinal substances in extemporaneous prescription, part 2 - dexpanthenol. Praktické lékárenství. 2010;6(4):192-197.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Paye M. Handbook of Cosmetic Science and Technology, 2nd Edition. Taylor & Francis Group, 2006. Go to original source...
    2. Wollina U, Nissen HP, Kubicki J. Antientzündliche Wirkungen von Dexpanthenol Akt Dermatol 2004; 30(11): 478-482. Go to original source...
    3. Litvik R. Úloha kožní bariéry u atopické dermatitidy. Farmakoterapie, 2008; 4(Suppl. 3): 11-21.
    4. Gloor M, Thoma K, Fluhr J. Dermatologische Externatherapie. Berlin, Heidelberg: Springer-Verlag, 2000. Go to original source...
    5. Proksch E, Nissen HP. Dexpanthenol enhances skin barrier repair and reduces inflammation after sodium lauryl sulphateinduced irritation. J Dermatol Treatment 2002; 13: 173-178. Go to original source... Go to PubMed...
    6. Proksch E, Feingold KR, Man MQ, Elias PM. Barrier function regulates epidermal DNA synthesis. J Clin Invest 1991; 87: 1668-1673. Go to original source... Go to PubMed...
    7. Schmuth M, et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, doubleblind study. Br J Dermatol 2002; 146: 983-991. Go to original source... Go to PubMed...
    8. Lokkevik E, et at. Skin treatment with bepanthen cream versus no cream during radiotherapy - a randomized controlled trial. Acta Oncol 1996; 35: 1021-1026. Go to original source... Go to PubMed...
    9. Goldinger, A. Strahleninduzierte Hautveränderungen - Teil 2: Praxisempfehlungen. Govi-Verlag und Stuttgart: Deutscher Apotheker-Verlag, 2007; 14, 112.
    10. Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders, Am J Clin Dermatol. 2002; 3(6): 427-433. Go to original source... Go to PubMed...
    11. Gloor M, Senger B, Gehring W. Wirkt eine Kombination von Dexpanthenol und Glycerin stärker hydratisierend als die Einzelkomponenten allein? Akt Dermatol 2002; 28: 402-405. Go to original source...
    12. Litvik R. Zásady léčby atopické dermatitidy, Farmakoterapie, 2009; 4: 421-432.
    13. Höger P. Kinderdermatologie: Differenzialdiagnostik und Therapie bei Kindern und Jugendlichen, Verlag für Medizin und Naturwissenschaften, 2007.
    14. http://www.sukl.cz/modules/medication/search.php (datum náhledu 4. 5. 2010).
    15. Deutscher Arzneimittel-Codex (DAC) 2007/Neues Rezeptur-Formularium (NRF). Band I-III. Pharmazeutischen Laboratorium des NRF. Eschborn: Govi-Verlag und Stuttgart: Deutscher Apotheker-Verlag, 2007.
    16. Rezepturhinweise NRF - Neues Rezeptur-Formularium, Pharmazeutische Zeitung, Govi-Verlag und Stuttgart: Deutscher Apotheker-Verlag, 2006.
    17. Sklenář Z, et al. Magistraliter receptura v dermatologii. 1. vyd. Praha: Galén, 2009.
    18. Garbe C, Reiman H. Dermatologische Rezepturen. Druhé vyd. Gregor Thieme Verlag, 2005. Go to original source...
    19. Altmeyer P. Therapielexikon Dermatologie und Allergologie. 2. vyd. Berlin, Heidelberg: Springer-Verlag, 2005. Go to original source...
    20. Sklenář Z. Nová emoliencia s obsahem močoviny v magistraliter přípravcích, Čes-slov Derm, 2010; 85: v tisku.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.